文献速递骨软组织肉瘤与黑色素瘤

纳武利尤单抗在Sonic Hedgehog抑制剂治疗失败或不耐受的晚期基底细胞癌患者中的安全性和疗效:UNICANCER AcSé NIVOLUMAB试验

Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
PubMed 文献 · Eur J Cancer · 2022-10-11

这项2期篮式研究纳入32例Sonic Hedgehog抑制剂治疗失败的晚期基底细胞癌患者(29例局部晚期,3例转移性),评估纳武利尤单抗的疗效与安全性。最佳完全缓解率为12.5%,部分缓解率18.8%,疾病稳定率43.8%。不良事件多为2或3级。

要点

  • 32例Sonic Hedgehog抑制剂治疗失败的晚期基底细胞癌患者接受纳武利尤单抗治疗。
  • 最佳完全缓解率12.5%,部分缓解率18.8%,疾病稳定率43.8%。
  • 不良事件多为2或3级,与转移性黑色素瘤治疗中观察到的不良事件略有不同。

核心结论

  • 纳武利尤单抗是晚期复发或难治性基底细胞癌患者的相关治疗选择。

研究设计与样本

  • 这是一项2期篮式研究(NCT03012581),评估纳武利尤单抗在32例Sonic Hedgehog抑制剂治疗失败的晚期基底细胞癌患者中的疗效和安全性。
  • 入组患者包括29例局部晚期基底细胞癌(91%)和3例转移性基底细胞癌(9%)。

主要发现

  • 全部患者既往接受过Sonic Hedgehog抑制剂治疗,53%的患者既往接受过化疗,75%接受过放疗。
  • 12周时,完全缓解率为3.1%,部分缓解率为18.8%,疾病稳定率为43.8%。
  • 纳武利尤单抗的最佳缓解率为完全缓解12.5%(4例患者)、部分缓解18.8%(3例患者)、疾病稳定43.8%(14例患者)。
  • 不良事件多为2或3级,与转移性黑色素瘤治疗中观察到的不良事件略有不同(糖尿病发生率更高,无甲状腺功能障碍)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Basal cell carcinoma (BCC) is the most common human malignancy. In most cases, BCC has slow progression and can be definitively cured by surgery or radiotherapy. However, in rare cases, it can become locally advanced or, even more rarely, metastatic. The alternative recommended treatments are Sonic Hedgehog pathway inhibitors; however, the response is often short-lived. METHODS: This was a phase 2 basket study (NCT03012581) evaluating the efficacy and safety of nivolumab in a cohort of 32 advanced BCC patients, enrolled after failure of Sonic Hedgehog inhibitors, including 29 laBCC (91%) and 3 mBCC (9%). RESULTS: Compared to previously published studies, our population consisted of severe patients with a poor prognosis because they had already received multiple lines of treatment: all patients received previous Sonic Hedgehog inhibitors, 53% of patients already had chemotherapy and 75% radiotherapy. At 12 weeks, we reported 3.1% of complete responses, 18.8% of partial responses, and 43.8% of stable diseases. The best response rate to nivolumab reached 12.5% of complete responses (four patients), 18.8% of partial responses (three patients), and 43.8% of stable diseases (14 patients). Adverse events (AE) were mostly grade 2 or 3, slightly different to the adverse events observed in the treatment of metastatic melanoma (higher rate of diabetes, no thyroid dysfunction). CONCLUSION: Nivolumab is a relevant therapeutic option for patients with advanced relapsing/refractory BCC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Véron M, Chevret S, Grob JJ, et al. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial. Eur J Cancer. 2022. PMID: 36335780. doi:10.1016/j.ejca.2022.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。